131 related articles for article (PubMed ID: 36325957)
1. Clinical and molecular characteristics of kinase domain duplications across diverse cancer types in the Chinese population.
Lai X; Yu R; Ou Q; Bao H; Wu X; Shao Y; Li Y; Zhang Y; Ding Q
Cancer Med; 2023 Mar; 12(5):6009-6015. PubMed ID: 36325957
[TBL] [Abstract][Full Text] [Related]
2. The landscape of kinase domain duplication in Chinese lung cancer patients.
Wu D; Xie Y; Jin C; Qiu J; Hou T; Du H; Chen S; Xiang J; Shi X; Liu J
Ann Transl Med; 2020 Dec; 8(24):1642. PubMed ID: 33490154
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC.
Wang J; Li X; Xue X; Ou Q; Wu X; Liang Y; Wang X; You M; Shao YW; Zhang Z; Zhang S
Int J Cancer; 2019 Jun; 144(11):2677-2682. PubMed ID: 30255937
[TBL] [Abstract][Full Text] [Related]
4. EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.
Gallant JN; Sheehan JH; Shaver TM; Bailey M; Lipson D; Chandramohan R; Red Brewer M; York SJ; Kris MG; Pietenpol JA; Ladanyi M; Miller VA; Ali SM; Meiler J; Lovly CM
Cancer Discov; 2015 Nov; 5(11):1155-63. PubMed ID: 26286086
[TBL] [Abstract][Full Text] [Related]
5. Molecular diagnosis and clinical outcome of a lung cancer patient with
Yang D; Han X; Li D; Cui S; Liu S; Wu X; Dai Z
Am J Transl Res; 2020; 12(10):6689-6693. PubMed ID: 33194065
[TBL] [Abstract][Full Text] [Related]
6. Structure-function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting.
Du Z; Brown BP; Kim S; Ferguson D; Pavlick DC; Jayakumaran G; Benayed R; Gallant JN; Zhang YK; Yan Y; Red-Brewer M; Ali SM; Schrock AB; Zehir A; Ladanyi M; Smith AW; Meiler J; Lovly CM
Nat Commun; 2021 Mar; 12(1):1382. PubMed ID: 33654076
[TBL] [Abstract][Full Text] [Related]
7. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
[TBL] [Abstract][Full Text] [Related]
8. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.
Shigematsu H; Lin L; Takahashi T; Nomura M; Suzuki M; Wistuba II; Fong KM; Lee H; Toyooka S; Shimizu N; Fujisawa T; Feng Z; Roth JA; Herz J; Minna JD; Gazdar AF
J Natl Cancer Inst; 2005 Mar; 97(5):339-46. PubMed ID: 15741570
[TBL] [Abstract][Full Text] [Related]
9. Role of the EGFR-KDD mutation as a possible mechanism of acquired resistance of non-small cell lung cancer to EGFR tyrosine kinase inhibitors: A case report.
He C; Wang Y
Mol Clin Oncol; 2022 Feb; 16(2):30. PubMed ID: 34987800
[TBL] [Abstract][Full Text] [Related]
10. Lung Adenocarcinoma Harboring
Li J; Yan J; Cao R; Du G; Zhao G
Front Oncol; 2020; 10():575739. PubMed ID: 33392076
[TBL] [Abstract][Full Text] [Related]
11. Lung Adenocarcinoma Patient Harboring
Zhao L; Wang Z; Du H; Chen S; Wang P
Front Oncol; 2021; 11():605853. PubMed ID: 33898306
[TBL] [Abstract][Full Text] [Related]
12. Deep Targeted Sequencing and Its Potential Implication for Cancer Therapy in Chinese Patients with Gastric Adenocarcinoma.
Yu P; Wang Y; Yu Y; Wang A; Huang L; Zhang Y; Liu W; Wu H; Yao M; Du YA; Cheng X
Oncologist; 2021 May; 26(5):e756-e768. PubMed ID: 33511732
[TBL] [Abstract][Full Text] [Related]
13. Clinical and molecular characteristics of Chinese non-small cell lung cancer patients with ERBB2 transmembrane domain mutations.
Fan Y; Qiu J; Yu R; Cao R; Chen X; Ou Q; Wu X; Shao YW; Nagasaka M; Zhang J; Ou SI
Mol Oncol; 2020 Aug; 14(8):1731-1739. PubMed ID: 32478891
[TBL] [Abstract][Full Text] [Related]
14. A Novel Oncogenic Driver in a Lung Adenocarcinoma Patient Harboring an
Chen D; Li XL; Wu B; Zheng XB; Wang WX; Chen HF; Dong YY; Xu CW; Fang MY
Front Oncol; 2020; 10():867. PubMed ID: 32656077
[No Abstract] [Full Text] [Related]
15. A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population.
Heredia D; Mas L; Cardona AF; Oyervides V; Motta Guerrero R; Galvez-Nino M; Lara-Mejía L; Aliaga-Macha C; Carracedo C; Varela-Santoyo E; Ramos-Ramírez M; Davila-Dupont D; Martínez J; Cruz-Rico G; Remon J; Arrieta O
Lung Cancer; 2022 Dec; 174():133-140. PubMed ID: 36379126
[TBL] [Abstract][Full Text] [Related]
16. Infantile fibrosarcoma with an EGFR kinase domain duplication: Underlining a close relationship with congenital mesoblastic nephroma and highlighting a similar morphological spectrum.
van Spronsen R; Kester LA; Knops RRG; van de Sande MAJ; van Leenders GJLH; de Laat PCJ; Stortelder E; Korpershoek E; van Noesel MM; Meister MT; Koerkamp MJAG; de Graaf N; Giovannoni I; Tops BBJ; de Krijger RR; Ter Horst SAJ; Flucke U; Alaggio R; Hiemcke-Jiwa LS
Ann Diagn Pathol; 2022 Apr; 57():151885. PubMed ID: 35032896
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive genomic profiling of lung cancer using a validated panel to explore therapeutic targets in East Asian patients.
Liu L; Liu J; Shao D; Deng Q; Tang H; Liu Z; Chen X; Guo F; Lin Y; Mao M; Kristiansen K; Ye M; He J
Cancer Sci; 2017 Dec; 108(12):2487-2494. PubMed ID: 28949084
[TBL] [Abstract][Full Text] [Related]
18. Genetic and epigenetic alterations of the LKB1 gene and their associations with mutations in TP53 and EGFR pathway genes in Korean non-small cell lung cancers.
Lee SM; Choi JE; Na YK; Lee EJ; Lee WK; Choi YY; Yoon GS; Jeon HS; Kim DS; Park JY
Lung Cancer; 2013 Aug; 81(2):194-9. PubMed ID: 23664447
[TBL] [Abstract][Full Text] [Related]
19. Concurrent gene alterations with EGFR mutation and treatment efficacy of EGFR-TKIs in Chinese patients with non-small cell lung cancer.
Hu W; Liu Y; Chen J
Oncotarget; 2017 Apr; 8(15):25046-25054. PubMed ID: 28212572
[TBL] [Abstract][Full Text] [Related]
20. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
VanderLaan PA; Rangachari D; Mockus SM; Spotlow V; Reddi HV; Malcolm J; Huberman MS; Joseph LJ; Kobayashi SS; Costa DB
Lung Cancer; 2017 Apr; 106():17-21. PubMed ID: 28285689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
